Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Biktarvy on Insulin Sensitivity in Healthy Volunteers
NCT04950530Phase 1Completed
- Sponsor
- Chelsea and Westminster Hospital NHS Foundation Trust
- Start
- Dec 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Chelsea and Westminster Hospital NHS Foundation Trust. Primary endpoint: Change in insulin sensitivity at Day 72. Started Dec 2022; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04950530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04950530.